Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
Nuvalent(NUVL) Prnewswire·2024-07-16 10:30Details for the presentations are as follows: Title: Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors Presentation Number: 1256MO Session Category: Mini oral session Session Title: NSCLC metastatic Presentation Date and Time: Saturday September 14, 2024, 10:30 – 10:35 CEST Location: Santander Auditorium – Hall 5 Presenter: Benjamin Besse, M.D., Ph.D. (Institut Gustav Roussy, Villejuif, France) Title: Profiling of Zidesamtinib and Other ROS1 Inhibitors in an Intracranial ...